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Abstract 
Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood 
vessels. Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance 
in the balance of these factors leads to cardiovascular disease including pulmonary arterial 
hypertension. Since it’s discovery in the 1980s concerted efforts have been made to make the 
best therapeutic utility of prostacyclin, particularly in the treatment of pulmonary arterial 
hypertension. This has centred on working out the detailed pharmacology of prostacyclin and 
then synthesising new molecules based on its structure that are more stable or more easily 
tolerated. In addition, newer molecules have been developed that are not analogues of 
prostacyclin but that target the receptors that prostacyclin activates. Prostacyclin and related 
drugs have without doubt revolutionised the treatment and management of pulmonary arterial 
hypertension but are seriously limited by side effects within the systemic circulation. With 
the dawn of nanomedicine and targeted drug or stem cell delivery systems it will, in the very 
near future, be possible to make new formulations of prostacyclin that can evade the systemic 
circulation allowing for safe delivery to the pulmonary vessels. In this way, the full 
therapeutic potential of prostacyclin can be realised opening the possibility that pulmonary 
arterial hypertension will become, if not curable, a chronic manageable disease that is no 
longer fatal. This review discusses these and other issues relating to prostacyclin and its use 
in pulmonary arterial hypertension.          
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Introduction 
Prostacyclin was discovered in 1976 by a group led by Salvador Moncada and John Vane1. 
Initially called prostaglandin (PG)X, prostacyclin was identified as an unknown lipid 
mediator formed by microsomes prepared from rabbit or pig aortas that inhibited human 
platelet aggregation and relaxed some preparations of isolated blood vessels. Early studies 
showed that PGX is the major metabolite of arachidonic acid in the arterial walls of a number 
of species, including man2. PGX was later identified as 5z-5,6-didehydro-9-deoxy-6,9a-
epoxyprostaglandin F1 and renamed as prostacyclin3. Early studies attributed prostacyclin 
release as the mechanism mediating the anti-thrombotic properties of the endothelium4 and its 
place as a fundamental mediator in cardiovascular health was set. A current (2014) PubMed 
search of the term ‘prostacyclin’ generates 17958 hits with 1992 hits for the terms 
‘prostacyclin’ and ‘pulmonary hypertension’. Pulmonary hypertension is a devastating, 
progressive and ultimately fatal condition with few treatment options, which, at best slow 
progression but do not cure the disease. Traditionally drugs have been designed to target the 
pulmonary vasculature as either vasodilators or inhibitors of smooth muscle remodeling. 
Most recently the right heart, which fails under the burden of extra work exerted on it by 
increased pulmonary pressures, has become a viable therapeutic target in the search for new 
drugs to treat pulmonary hypertension. 
 
This review will cover what is known about the synthetic and receptor pathways associated 
with prostacyclin and how this knowledge has been applied and translated to produce 
treatments. Specifically the review will discuss how the known actions of prostacyclin 
provide a compelling case for its utility for treatment of both pulmonary vessels and the right 
heart. The review will also identify the limitations of prostacyclin therapies and speculate 
upon how modern medical technologies might be applied to improve its utility in this disease. 
Finally, with the idea that pulmonary arterial hypertension may, in the future, be treated with 
stem cell therapies to supplement organ regeneration and/or transplant, the potential role of 
prostacyclin in these approaches will be highlighted. 
 
Synthesis of prostacyclin 
Endothelial cells are the predominant source of prostacyclin in the body and prostacyclin is 
the main eicosanoid made by endothelial cells. Prostacyclin is synthesised from the 20 carbon 
fatty acid (20:4) arachidonic acid by the concerted actions of cyclo-oxygeanse (COX) and 
prostacyclin synthase5 (Figure 1). Arachidonic acid is not normally free in cells but acetylated 
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in membrane phospholipids. The first step in prostacyclin release is activation of enzymes 
that liberate arachidonic acid from membranes. The best-studied pathway for arachidonic 
acid liberation involves phospholipase A2 (Figure 1). There are multiple forms of 
phospholipase A2 but cytosolic forms (cPLA2) and, in some circumstances, calcium-
independent PLA2 (iPLA2) are thought to drive arachidonic acid liberation in endothelial 
cells. Arachidonic acid can also be liberated through a second pathway after phospholipase C 
cleaves an inositol triphosphate group, giving diacylglycerol (DAG), which can then be 
hydrolyzed by lipases to monoacylglycerol and then to free arachidonic acid and glycerol.  
 
Once free inside the cell arachidonic acid is metabolized by various enzymatic and non-
enzymatic routes to eicosanoids (or icosanoids; lipid mediators derived from 20 carbon fatty 
acids). Prostacyclin is a prostanoid member of the eicosanoid family produced by a two-step 
reaction metabolized by COX. In the first step arachidonic acid is converted to prostaglandin 
(PG)G2 via an oxygenase reaction and then in the second step, to PGH2 by a peroxidase 
reaction.  PGH2 is relatively unstable but within cells provides the substrate for a range of 
synthase enzymes downstream of COX (Figure 1). It is the relative expression of these PG 
synthase enzymes that critically dictate the profile of prostanoids released by a given cell type 
under different conditions. For example, endothelial cells and platelets both express the 
isoform COX-1 but prostacyclin synthase is highly expressed in endothelial cells with little or 
no thromboxane synthase. In contrast, in platelets thromboxane synthase is highly expressed 
whilst there are negligible levels of prostacyclin synthase. As a result, despite both tissue 
types being high expressers of COX-1, the prostanoid products they produce are highly 
polarized and, in this way, perform diametrically opposed functions within the cardiovascular 
system. Like COX, prostacyclin synthase is a P450 enzyme, expression of which in 
endothelial cells, is regulated by shear stress and growth factors.  
 
Pulmonary arterial hypertension is classically associated with reduced vasodilators (including 
prostacyclin) and increased vasoconstrictors, which is why current therapies rely so heavily 
on manipulation of vasoactive pathways. Specifically, in terms of eicosanoids, pulmonary 
arterial hypertension is associated with reduced urinary markers of prostacyclin and increased 
markers of thromboxane6. This is in line with reduced prostacyclin synthase in lungs of 
patients with pulmonary arterial hypertension7. Further, transgenic mice overexpressing 
prostacyclin synthase or mice inoculated with prostacyclin synthase gene8, 9 are protected 
from development of disease symptoms10. Prostacyclin synthase gene delivery in the form of 
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genetically modified stem cells has also been reported to protect against development of 
experimental pulmonary arterial hypertension11, 12. 
 
Once formed by endothelial cells prostacyclin doesn’t simply diffuse out of cells but is 
exported by highly regulated transporter systems, most likely of the ABC13 class with the 
likely member of this class most used for prostanoids, including prostacyclin, being 
multidrug resistance protein 4 (MRP4/ABCC4)14. Once released from cells prostacyclin is 
then free to act on receptors to mediate its actions. The idea that pulmonary arterial 
hypertension may be associated with reduced secretion of prostacyclin at the level of a 
transporter has not been addressed and, where tested, inhibition of MRCP4 leads to 
protection in animal models attributed to an action on cGMP/cGMP transport15. Nevertheless, 
the lack of literature in this area suggests that elucidation of precise mechanisms of 
prostacyclin flux in pulmonary vessels during disease may provide insight and new drug 
targets. 
 
Receptor pathways utilized by prostacyclin and implications for treatments in 
pulmonary arterial hypertension 
Prostanoid signaling is mediated by selective cell surface receptors and in some tissues by 
activation of cytosolic PPAR receptors. For prostacyclin, the cell surface receptor is the G-
protein coupled ‘IP’ receptor (Figure 2). IP receptors are coupled to Gs leading to activation 
of adenylate cyclase and subsequent conversation of ATP to the second messenger cAMP 
(Figure 2). The biological effects of cAMP in a given tissue, which are diverse, are mediated 
by activation of cAMP-dependent protein kinases (also known as protein kinase A) and 
Exchange protein activated by cAMP (Epac; Figure 2). In vascular smooth muscle cAMP 
mediates relaxation and reduces proliferation and in platelets reduces thrombosis via 
regulation of calcium levels and associated pathways. Protein kinase A and Epac act 
synergistically to inhibit vascular smooth muscle cell proliferation16 and whilst pulmonary 
artery smooth muscle cells express both of these pathways, preliminary studies suggest that 
Epac is down regulated in pulmonary hypertension17.  
 
As with other prostanoids, the complicating pharmacological feature of prostacyclin is that, 
whilst its acts preferentially on its designated subtype (i.e. IP) receptors, it can cross over and 
activate any of the other prostanoid receptors in particular circumstances (Figure 2). This 
means that, for example, where IP receptors are limiting, prostacyclin can activate 
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thromboxane (TP) receptors. As mentioned above, the opposing properties of thromboxane 
and prostacyclin in the cardiovascular system are critical to the maintenance of vascular 
health. This balance is broken when thromboxane is produced in excess, or, similarly where 
IP receptors are saturated. In these settings prostacyclin becomes a mimetic for thromboxane 
inducing vasoconstriction. Prostacyclin and related drugs can also cross over onto constrictor 
EP and FP receptors, which, as with TP, can limit the dilator actions of prostacyclin, as well 
as dilator EP and DP receptors which may have a beneficial effect. This issue of specificity is 
of relevance to the use of prostacyclin drugs to treat pulmonary arterial hypertension since 
there is, as with all pharmaceutical preparations, the danger of overriding local sensing 
pathways. 
 
The existence of multiple IP receptor subtypes has been suggested in some tissues but these 
observations are based on pharmacological studies and have not been validated at the gene 
level. Nonetheless, the authors of a recent study claim to have conclusively identified two IP 
receptor subtypes using a human airway epithelial cell line exposed to a host of IP agonists in 
the presence or absence of a selective IP antagonist18. Whilst this observation is potentially 
very important, it remains to be seen whether the distinct IP receptor subtypes can be 
identified in other human cells. 
 
The potential for GPCRs to homo- and hetero-dimerize is well-established. IP receptors can 
form homodimers via the interactions of disulphide bonds19. Importantly IP receptors may 
also form heterodimerize with thromboxane TP receptors 20. The IP-TPα complex has been 
suggested to have a protective role in promoting a “PGI2-like” response from TPα activation 
by TP ligands20. After activation, IP receptors are desensitized by PKC-dependent 
phosphorylation21 and receptor internalization22, which constitute endogenous pathways to 
regulate and limit prostacyclin signalling. As is common for drugs acting on natural receptor 
pathways the prospect of IP desensitization/internalization may be a confounding factor in 
utilizing prostacyclin analogues as therapeutic interventions and, as discussed can shunt 
biological responses away from dilator to constrictor pathways. Evidence of desensitisation 
of IP receptors and/or their down stream pathways has been noted in clinical studies. In line 
with this continuously infused epoprostenol is associated with tolerance in patients with 
severe pulmonary hypertension, and dose adjustments have to be made to maintain clinical 
effects23, 24. Indeed, in patients with pulmonary arterial hypertension secondary to COPD the 
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dilator effects of epoprostenol on pulmonary pressures were subject to tachyphylaxis within 
24 hours25.  
 
Prostacyclin is also a ligand for the cytosolic nuclear receptor PPARβ26 (Figure 2). PPARβ is 
considered to be anti-inflammatory in a number of settings where it acts by genomic and non-
genomic mechanisms26 (Figure 2). Importantly for the treatment of pulmonary arterial 
hypertension, the prostacyclin drug, treprostinil, activates PPARβ in platelets27, lung 
fibroblasts28 and blood vessels29. Work from our group and others has also shown that 
selective, non-IP, PPARβ agonists relax pulmonary artery smooth muscle cells30 and prevent 
hypertension in an hypoxic rat model29. In animal models we found that whilst the PPARβ 
agonist GW0742 prevented pulmonary arterial hypertension, reducing right heart 
hypertrophy, it did not reduce muscularization of vessels in the lung29. This suggested to us 
that PPARβ agonists might have a protective action directly on the right heart in pulmonary 
arterial hypertension. Recently we, with collaborators, tested this idea using a pulmonary 
artery banding model where workload is applied to the right heart mechanically without any 
contribution from pulmonary pressure per se31. Of direct relevance, others have shown that 
PPARβ activation in adult hearts facilitates mitochondrial function and improves cardiac 
performance under pressure-overload conditions32. In our study, GW0742 prevented right 
heart remodeling and transcripomic profiling of heart tissue suggested that the mechanism 
was classically genomic involving the PPAR target gene Angptl431. Angptl4 is a member of 
the angiopoietin-like family and regulates angiogenesis and lipid metabolism. While no data 
currently exist relating Angptl4 to idiopathic pulmonary arterial hypertension, it has recently 
been associated with high-altitude adaptation in Tibet 33 and Angptl4 is associated with left 
heart failure where it protects against myocardial infarction and no reflow through 
preservation of vascular integrity 34. These observations support the idea that Angptl4 may be 
a viable mechanism by which PPARβ activation leads to cardioprotection and suggest that 
this pathway may be therapeutically important in other forms of heart failure, such as seen in 
pulmonary arterial hypertension. This is an interesting notion since our work shows this is 
independent of actions on vessels which means that activation of PPARβ could be a good 
adjunct therapy to current drugs acting on vasodilator pathways. In our work we have 
suggested that the time could be right for a clinical study to assess the effects of PPARβ in 
pulmonary arterial hypertension, since there are orally active drugs available that have 
already been used man35. However, this needs to be treated with extreme caution for two key 
reasons. Firstly, PPARβ drugs may negatively interact with current drugs29 and secondly 
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PPARβ drugs are associated with increased risk of cancer36, 37 and warnings have been issued 
for their use, particularly directed at sports performance dosing where illicit procurement of 
drug maybe considered by athletes.  
 
Role of COX-1 and COX-2 in prostacyclin generation and implications for pulmonary 
arterial hypertension 
As described above, prostacyclin is formed from PGH2 produced by the enzyme COX. COX 
has two isoforms COX-1, which is constitutively expressed and COX-2 that is induced at the 
site of inflammation38. COX-1 is the predominate enzyme present in endothelial cells and its 
loss in vessels virtually abolishes release of prostacyclin39-41. This is also true in conditions of 
inflammation associated with atherosclerosis42.  
 
However, COX-2 takes over from COX-1 as the driver for prostacyclin release under 
conditions of gross systemic inflammation such as that associated with sepsis43. Outside large 
vessels COX-2 is expressed in some key tissues, including in the lung40. It is now accepted 
that pulmonary arterial hypertension is, at least in part, driven by inflammatory cytokines44-47 
and interferon48, 49. With this in mind our group was the first to suggest that induction of 
COX-2 by cytokines may be implicated in pulmonary arterial hypertension50. Others showed 
similar data in cells relevant to pulmonary arterial hypertension48, 51-53. If prostacyclin is the 
main product of cells expressing COX-2 in the lungs in pulmonary arterial hypertension it is 
likely to form a protective responses. This idea is supported by data showing a detrimental 
effect of COX-2 gene deletion in mouse models of pulmonary arterial hypertension54, 55. 
However, if prostacyclin synthase is overwhelmed and/or if the IP receptor population is 
saturated, COX-2 will drive a constrictor response and this may explain a protective effect of 
COX-2 inhibitors in other experimental models56. It should be noted however, that there is no 
evidence to suggest that this phenomenon predominates and the role of COX-2 and 
associated prostacyclin release in human pulmonary arterial hypertension remains the subject 
of investigation. 
 
Prostacyclin as a drug to treat pulmonary arterial hypertension 
Pulmonary arterial hypertension is rare, but fatal, with mean survival rates without therapy of 
less than 2 years. The introduction of prostacyclin therapies in the early 1990s has led to 
increased survival rates to around 5-7 years with some patients living with pulmonary arterial 
hypertension on prostacyclin therapy for more than 10 years. The features of pulmonary 
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arterial hypertension include reduced prostacyclin/thromboxane balance, constriction, 
remodeling and thrombosis. With these features in mind the therapeutic utility of prostacyclin 
(also known as epoprostenol) was assumed very early in the field and in 1984 a placebo 
controlled trial was conducted where prostacyclin was continuously infused in patients with 
peripheral vascular disease57. This paved the way for a landmark trial in 1996 where 
prostacyclin, was infused intravenously for 12 weeks in patients with pulmonary arterial 
hypertension23. 41 patients received prostacyclin and 40 the conventional treatment at the 
time, which consisted of anticoagulants, oral vasodilators, diuretic agents, cardiac glycosides, 
and supplemental oxygen. Exercise capacity, measured using the 6 minute walk test, was 
improved in all 41 patients treated with prostacyclin but was reduced in the 40 patients 
treated with conventional therapy. Importantly, mortality was improved in the patients 
administered prostacyclin. However, serious side effects were noted in the prostacyclin arm, 
which included catheter associated sepsis. Epoprostenol (FLOLAN®) remains a therapeutic 
option in the treatment of pulmonary arterial hypertension but is seriously limited by its very 
short half-life at room temperature and side effects associated with the need for continuous 
infusion requiring permanent intravenous catheter and pump (Figure 3). To address some of 
these limitations a number of more stable prostacyclin analogues have been developed for the 
treatment of pulmonary arterial hypertension (Figure 4). These include iloprost (Ventavis®) 
and treprostinil (Remodulin®), which together with epoprostenol constitute the current 
prostacyclin therapies in patients with pulmonary arterial hypertension (Figure 3). 
Treprostinil, which has similar pharmacodynamics to epoprostenol is more stable and can be 
administered subcutaneously and intravenously. Iloprost is administered as an inhaled 
preparation using a nebulizer 6-9 times a day. Treprostinil is also available in and inhaled 
formulation (TYVASO®; Figure 3) given approximately each 4 hours.  
 
Prostacyclin and combination therapy in pulmonary arterial hypertension 
Despite their effectiveness and because of their limitations and side effects, prostacyclin 
drugs are generally restricted to patients with pulmonary arterial hypertension and who are in 
functional class III or IV58. Intravenous epoprostenol is often the preferred drug with 
intravenous treprostinil given as an alternative. Inhaled iloprost is generally reserved for 
patients for whom intravenous therapy is not acceptable or appropriate. As prostacyclin drugs 
are reserved for patients with severe pulmonary arterial hypertension in most cases they will 
be given in combination with either a phosphodiesterase type 5 (PDE5) inhibitor and/or an 
endothelin receptor antagonist (ETRA)58. The utility and mechanism of action of PDE5 
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inhibitors59, 60 and ETRAs61 are reviewed in detail elsewhere. However, in brief, PDE5 
inhibitors work by increasing the bioactivity of endogenously released NO. NO, like 
prostacyclin, is a vasodilator, but acts on a parallel signaling pathway via activation of 
soluble guanylate cyclase leading to increases in the second messenger cGMP. PDE5 
removes cGMP, thus blocking PDE5 potentiates NO signaling. The effects of NO and 
prostacyclin are additive in blood vessels60 and work in powerful synergy in platelets60, 62. 
ETRA drugs, on the other hand, work independently of the NO or prostacyclin pathways by 
blocking the actions of the powerful constrictor peptide endothelin-1. It is not clear how the 
pharmacology of these three pathways affects particular combinations of drugs in pulmonary 
arterial hypertension and there are no validated biomarkers that can predict which drugs will 
work together optimally. However, this is an area of research that our group and others are 
investigating using endothelial cells grown from blood progenitors allowing insights into 
vascular function in patients with pulmonary arterial hypertension63, 64. 
 
Limitations of prostacyclin drugs in pulmonary arterial hypertension 
As with other treatments for pulmonary arterial hypertension prostacyclin drugs are very 
expensive with estimated annual costs of $30,000 to more than $200,000 per patient per year 
in the United States. However, the main limitations of prostacyclin drugs for those that 
require the drug to be infused are infection and pain at the site of injection. In addition all 
forms of prostacyclin drugs are associated with side effects such as systemic hypotension, 
flushing, jaw pain and nausea. Intense research efforts are ongoing to address these 
limitations and include the development of small molecule, non-prostacyclin, selective IP 
receptor agonists most notably selexipag (Figure 4). Selexipag is a potent, orally active a pro-
drug whose active metabolite, MRE269 (ACT-333679), is a selective prostacyclin IP receptor 
agonist. Unlike prostacyclin analogue drugs, because selexipag is specific for the IP receptor, 
it has little or no effect on other prostanoid receptors. This means that where drugs based on 
prostacyclin structures may be limited by underlying constrictor actions on EP, TP or FP 
receptors, selexipag targets dilator IP pathways only. However, this high specificity for IP 
receptors means selexipag will also fail to activate DP receptors and PPARβ that may 
contribute to the efficacy of other prostacyclin drugs. Nonetheless, a phase II proof of 
concept study showed favorable results65 and in 2009 the GRIPHON66, (Prostacyclin (PGI2) 
Receptor agonist In Pulmonary arterial HypertensiON) trial was initiated by Actelion to test 
the utility of selexipag in a randomized, multicenter, double-blind, placebo-controlled trial in 
patients with pulmonary arterial hypertension. In June 2014 Actelion announced that initial 
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analysis of the GRIPHON study showed that selexipag decreased the risk of a 
morbidity/mortality and that the overall tolerability profile of selexipag in GRIPHON was 
consistent with existing prostacyclin therapies. According to the Actelion website67 in 
December 2014 marketing authorizations will be submitted to the European Medicines 
Agency (EMA) for selexipag (Uptravi®) in the treatment of pulmonary arterial hypertension 
with similar applications pending to the US Food and Drug Administration (FDA). However, 
even if oral dosing with selexipag proves to be as efficacious as prostacyclin drugs dosed by 
infusion or inhalation, it is still limited by side effects common to prostacyclin therapy due to 
its actions on the systemic circulation. In the wake of success with orally active IP-selective 
selexipag, most recently the FDA approved the first orally active formulation of a 
prostacyclin drug, treprostinil (Orenitram™). Orenitram™ is treprostinil in an extended-
release tablet formulation for the treatment of patients with pulmonary arterial hypertension68. 
The approval comes after the FREEDOM studies69, 70. Whilst current data in patients not 
previously taking prostacyclin drugs are disappointing, studies show that in some patients 
oral treprostinil may successfully replace existing use of continuously infused drug. 
However, as with selexipag, oral dosing does not prevent side effects and future studies and 
development in formulations will be needed to improve prostacyclin drugs in all their guises. 
 
Future of prostacyclin drugs in pulmonary arterial hypertension 
Clearly prostacyclin drugs in all their forms have proven utility in pulmonary arterial 
hypertension but are severely limited by route of delivery and effects of on the systemic 
circulation. Attempts to circumvent the need for drug infusion have been successful with 
drugs such as inhaled treprostinil and iloprost and orally active selexipag, but the systemic 
side effects remain the limitation in realizing the full potential of this class of drugs. One 
approach being adopted in other human diseases is nanomedicine, where targeted drug 
delivery can improve efficacy and over come side effects (Figure 5). The use of 
nanomedicine technology has, in some cases, revolutionized drug formulations for treatment 
of cancer71. Nanomedicine is a relatively young science and can be defined as the medical 
application of nanotechnology, in the case of drug delivery systems this equates to the use of 
formulations in the nanometer range. As the field grows the types of potential formulations 
suitable to encapsulate drugs increases. The idea that this technology can be applied to drugs 
for pulmonary arterial hypertension was recently reviewed72 but the idea remains relatively 
novel and untested. Nevertheless, we suggest that the following approaches may solve the 
current limitations of prostacyclin drugs. Firstly a safe and effective encapsulation of 
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prostacyclin drug within a suitable nanoparticle to evade the systemic circulation is required. 
This may be enough to allow specific targeting of pulmonary vessels if similar characteristics 
of local tissue environment exist to those in tumors. In tumors some nanomedcines can 
accumulate because of increased vascular leak and reduced lymphatic drainage. However, in 
the case of specific delivery of a prostacyclin drug to affected pulmonary vessels additional 
molecular engineering may be required. One approach to this would be to use an antibody-
drug conjugate (Figure 5). Here it would first be necessary to identify a specific antigen 
expressed locally within pulmonary vessels, manufacture and humanize the antibody. This 
may be possible by using comparative systems approaches such as proteomics, recently used 
to identify translationally controlled tumor protein (TCTP) as a marker of pulmonary arterial 
hypertension64. These, of course, are not trivial tasks and would require the concerted efforts 
of chemists, bioengineers, pharmacologists and clinicians.  
 
Future application for the prostacyclin pathway in stem cell and organ regeneration 
therapies 
Current therapies have had dramatic effects at increasing the life expectancy of patients with 
pulmonary arterial hypertension. However, ultimately, in most cases, these fail and in some 
patients having a lung transplant is the only therapeutic option. Needless to say this is not a 
perfect solution nor is it one that can benefit most patients. With this in mind there are 
increasing efforts in the use of stem cell therapy to treat pulmonary arterial hypertension. 
This may be either at the level of giving stem cells in an attempt to repopulate the diseased 
vessels in the pulmonary vasculature or, at the most ambitious end of the spectrum, to grow 
lung tissue in bio incubators for transplant.   
 
Prostacyclin pathways play a potentially important role in these approaches. Any stem cell 
therapy in pulmonary arterial hypertension would require a fully functioning 
COX/prostacyclin synthase pathway and would similarly require fully functioning 
prostacyclin receptors to be present. This type of approach in stem cell and gene therapy has 
been reviewed elsewhere73 but remains very much at the theoretical and experimental stage. 
 
Summary and conclusions 
Prostacyclin is a multifaceted cardioprotective hormone released by the endothelium. Since 
its discovery in the 1980s prostacyclin has been the subject of thousands of publications yet 
we are still discovering new insights into its biology and pharmacology. Prostacyclin remains 
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arguably the most effective therapy for patients with pulmonary arterial hypertension but 
current drugs based on its pharmacology have serious limitations. It is hoped that in the future 
specific targeting of prostacyclin drugs alone, or in combinations with other medications can 
resolve these limitations and allow for less frequent but more effective administration of high 
doses of drug, that will, if not cure this disease, at least convert it to an effectively managed 
non-fatal condition. 
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Figure 1: Synthesis of prostacyclin. Prostacyclin (PGI2) is synthesized from arachidonic 
acid (AA) by the concerted actions of the enzymes cyclo-oxygenase (COX) and prostacyclin 
synthase. AA is liberated by from plasma phospholipids by phospholipase enzymes where it 
is metabolized to prostaglandin (PG)H2 by COX. PGH2 is then further metabolized by 
prostacyclin synthase to PGI2, by PGE2 synthases/isomerases to PGE2 or thromboxane 
synthase to thromboxane (TXA2).  
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 Figure 2: Signaling pathways utilized by prostacyclin (PGI2). PGI2 acts preferentially on 
cell surface IP receptors that activate adenylate cyclase to convert ATP to cAMP. cAMP 
activates protein kinase A and Exchange protein activated by cAMP (Epac). In blood vessels 
and platelets this results in calcium sequestration and inhibition of activation equating to 
vessel relaxation, reduced remodeling and reduced thrombosis respectively. These signaling 
events also reduce inflammation. In the cytosol, PGI2 activates PPARβ receptors which work 
by three discreet pathways. Firstly, PPARβ binds to RXR to drive transcription of target 
genes. Secondly it represses BCL6 and thirdly, when activated it can bind and repress PKCα. 
Activation of PPARβ can lead to similar functional effects to activation of IP receptors, 
although by these very different pathways. When PGI2 is present in excess and these 
pathways are overwhelmed it can activate other prostanoid receptors leading to IP-type 
signaling in the case of EP2, EP4 and DP or to functionally opposing effects in the case of TP, 
FP, EP1 or EP3 receptors. 
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Figure 3: Pulmonary arterial hypertension drugs acting on prostacyclin pathways. 
Synthetic prostacyclin (epoprostenol), injected treprostinil, inhaled treprostinil (itreprostinil), 
oral treprostinil (otreprostinil) or iloprost are drugs based on the structure of prostacyclin, 
which activate the IP receptor, but may also activate other prostaglandin receptors (PGRs). 
Selexipag is a non-prostacyclin drug given orally which selectivity activates the IP receptor. 
GW0742 is a non-prostanoid, non-IP small molecule drug that activates PPARβ in 
experimental models of pulmonary hypertension. 
 
  
Prostacyclin,drugs:,
•  Epoprostenol*(FLOLAN®)*
•  Trepros4nil*(Remodulin®)**
•  iTrepros4nil*(TYVASO®)*
•  oTrepros4nil*(Orenitram™)*
•  Iloprost*(Ventavis®)**
Non2prostacyclin,(IP),drugs:,
•  Selexipag*(Uptravi®)*
Non%prostacyclin.(PPARβ).drugs.
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*
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*
*
Ac4vate*PPARβ*
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Figure 4: 2D (a-d) and 3D (e-f) structures of prostacyclin drugs epoprostenol (a,e), 
remodulin (b,f) and iloprost (c,g) and the non-prostacyclin IP agonist pro-drug 
selexipag (d,h). The active metabolite of selexipag is MRE269 where the terminal nitrogen is 
replaced with oxygen (see insert; panel d). Each of the listed drugs has similar molecular 
weights. 
•  Selexipag!
•  C26H32N4O4S!
•  Mr!496.6!
•  MRE,269,
•  !C25H29N3O3!
•  Mr!419.5!
!
•  Iloprost,
•  ,C22H32O4!
•  Mr!360.5!
•  Trepros6nil,
•  C23H34O5!
•  Mr!390.5!
,
•  Epoprostenol,
•  C20H32O5!
•  Mr!352.4!
,
MRE269,
a ! ! ! ! !b ! ! ! ! !c ! ! ! ! !d!
!
!
!
!
!
!
!
e ! ! ! ! !f ! ! ! ! !g ! ! ! ! !h !
! ! !!
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Figure 5: Targeted delivery of prostacyclin to affect pulmonary vessels in disease. 
Prostacyclin could be encapsulated to form a nanomedicine formulation to protect it from 
metabolism and the systemic circulation. Attachment of an antibody directed at a specific 
antigen within pulmonary arteries would allow for targeted delivery and evasion of the 
systemic circulation. 
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